CORONA vs NEPHROPLUS: Stock Comparison
Corona Remedies Ltd is the larger company by market capitalisation. Corona Remedies Ltd shows a lower P/E, a higher ROE and a higher dividend yield, while Nephrocare Health Services Ltd shows lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
CORONA leads 7; NEPHROPLUS leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | CORONA | NEPHROPLUS |
|---|---|---|
| Live Price | ₹2,097.3 | ₹697.35 |
| Day Change | -2.41% | 1.47% |
| Volume | 14,193 | 1.46 L |
| 52-Week High | ₹2,270.1 | ₹769.75 |
| 52-Week Low | ₹1,336.6 | ₹446 |
| Distance from 52W High | -7.61% | -9.41% |
Valuation
| Metric | CORONA | NEPHROPLUS |
|---|---|---|
| Market Cap | ₹12,843 Cr | ₹6,991 Cr |
| P/E Ratio | 66.01x | 89.97x |
| P/B Ratio | 17.59x | 6.19x |
| EPS | ₹30.3 | ₹7.66 |
| Book Value | ₹122 | ₹111 |
| Dividend Yield | 0.49% | 0% |
Growth
| Metric | CORONA | NEPHROPLUS |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 20.2% | 21.2% |
| Qtr Profit Growth | 43.7% | 22.1% |
Profitability & Leverage
| Metric | CORONA | NEPHROPLUS |
|---|---|---|
| ROE | 29.5% | 9.06% |
| ROCE | 33.3% | 15.5% |
| Net Margin | 13.19% | 7.69% |
| Operating Margin | 21% | 22.4% |
| Debt to Equity | 0.22x | 0.07x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | CORONA | NEPHROPLUS |
|---|---|---|
| Promoter Holding | 69% | 21.07% |
| FII Holding | 3.63%▲ 1.38 pp | 8.78%▼ 1.16 pp |
| DII Holding | 12.9%▲ 5.88 pp | 9.05%▲ 0.4 pp |
| Public Holding | 14.48%▼ 7.26 pp | 18.32%▲ 0.76 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Corona Remedies Ltd and Nephrocare Health Services Ltd.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.